Cover Image

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Background: Outpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration. Methods: ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk...

Full description

Saved in:
Bibliographic Details
Main Authors: Katya Corado (Author), Kara Chew (Author), Mark Giganti (Author), Ying Mu (Author), Courtney Fletcher (Author), Judith Currier (Author), Eric Daar (Author), David Wohl (Author), Jonathan Li (Author), Carlee Moser (Author), Justin Ritz (Author), Arzhang Javan (Author), Gene Neytman (Author), Marina Caskey (Author), Michael Hughes (Author), Davey Smith (Author), Joseph Eron (Author), ACTIV-2/A5401 Study Team (Author)
Format: Book
Published: Case Western Reserve University, 2024-05-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items